Change of ownership in Hansa Medical

Farstorps Gård AB, previously the largest shareholder in Hansa Medical AB, has
sold 3,947,368 shares in Hansa Medical, representing approx. 15 per cent. of the
total number of shares and votes outstanding in the company to a selected number
of Swedish and international institutional investors, including specialist
healthcare funds Rhenman & Partners, Hjärt-Lungfonden and others.
Important information
The information in this press release is not directed at persons located in
Australia, Canada, Hong Kong, Japan, New Zealand, the Republic of Korea,
Singapore, South Africa, Switzerland, the United States or any other country
where the offer or sale of subscription rights, interim shares or new shares is
not permitted. The information may not be published or distributed, directly or
indirectly, in or into, any of the aforementioned countries or any other country
where such action is wholly or partially subject to legal restrictions or where
such action would require additional prospectuses, other offer documentation,
registrations or other actions in addition to what follows from Swedish law. Nor
may the information be forwarded, reproduced or disclosed in such a manner that
contravenes such restrictions or gives cause to such requirements. Failure to
comply with these instructions may result in a violation of the United States
Securities Act of 1933, as amended (“Securities Act”) or laws applicable in
other jurisdictions.

The information in this press release does not contain or constitute an
invitation or an offer to acquire, sell, subscribe for or otherwise trade in
shares, subscription rights or other securities in Hansa Medical AB. No
subscription rights, interim shares or new shares will be registered under the
Securities Act or in accordance with any other rules or regulations in any other
country than Sweden and may not be transferred or offered for sale in the United
States or any country where such transfer or offer may be prohibited, or to
persons resident in any such country or on account of such persons, other than
pursuant to an exemption from, or in a transaction not subject to, the
registration requirements of the Securities Act or similar legislation in
another country, respectively.

Following the placement, Farstorps Gård AB’s ownership amounts to 7,122,952
shares, representing approx. 27 per cent of the total number of shares and votes
outstanding in Hansa Medical AB (publ). Farstorps Gård AB has agreed not to sell
any additional Hansa Medical shares until 31 August 2015, subject to certain
customary exceptions.

The rights issue announced on February 23, 2015 is fully guaranteed by
subscription undertakings from shareholders, including Nexttobe AB, and
underwritings.

As previously announced, the Board of Hansa Medical AB (publ) has decided,
pursuant to authorisation by the 2014 annual general meeting, to issue at most
6,482,400 new shares with pre-emptive rights for current shareholders. The
rights issue will, provided full subscription, provide Hansa Medical with
approx. SEK 246 million before deduction for issue related costs.

The Company’s largest shareholder, Nexttobe AB, has committed to subscribe and
pay for its pro rata share of the rights issue. Together with subscription
undertakings from other shareholders, among which several are new owners, and
underwriting, the issue is fully covered by subscription undertakings and
underwritings.

About IdeS
IdeS, a unique molecule with a novel mechanism, is a bacterial enzyme that
cleaves human IgG antibodies. IdeS degrades all IgG specifically, swiftly and
efficiently. IdeS has been tested for safety and efficacy in numerous in vitro
and in vivo models. During 2013, a Phase I clinical trial on 29 healthy subjects
was conducted, demonstrating IdeS as efficacious and well tolerated with a
favorable safety profile. During 2014 and 2015, a Phase II clinical trial in
sensitized patients awaiting kidney transplantation has been conducted.
Preliminary data shows that IdeS has very good efficacy in highly sensitized
patients on the kidney transplant waitlist. The study shows that IdeS has the
capacity to make sensitized patients eligible for transplantation by decreasing
HLA antibodies to levels acceptable for transplantation. In addition to
transplantation, IdeS has potential indications within a variety of rare
autoimmune diseases including anti-GBM disease. IdeS is protected by several
patents and has been published in numerous peer review journals.

The information in this press release is disclosed pursuant to the Securities
Markets Act or the Financial Instruments Trading Act. The information was
released for public disclosure on February 23, 2015 at 08.45.
For further information, please contact:
Hansa Medical AB
Fredrik Lindgren, President and CEO
Mobile: 46 705 61 61 77
E-mail: fredrik.lindgren@hansamedical.com
www.hansamedical.com
About Hansa Medical AB
Hansa Medical is a biopharmaceutical company focused
on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading
enzyme in clinical development, with potential use in transplantation and rare
autoimmune diseases. Other projects include HBP (a market introduced diagnostic
marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in
pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's
share (HMED) is listed on NASDAQ First North in Stockholm with Remium Nordic AB
as Certified Adviser. Major shareholders are Farstorps Gård AB and Nexttobe AB.